Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo Statement of Significance: Multiple recent studies have highlighted the immunosuppressive impact of MUC16/CA125 on antibodies immune effector function incl

Antibody Therapeutics (IF=4.5, Oxford University Press)
🔥🔥 Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
academic.oup.com/abt/article/...
#ADCC #CDC #CD20 #MUC16 #CA125 #rituximab #CD16